Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox

Clinical Lymphoma and Myeloma

Volumn 7, Issue 3, 2006, Pages 199-204

  Chin, Kevin M ^a   Foss, Francine M ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Interleukin 2 receptor; Lactate dehydrogenase; Mycosis fungoides; S zary syndrome

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEXAROTENE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHENHYDRAMINE; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; METHOTREXATE; PARACETAMOL; PSORALEN; PURINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ELECTRON THERAPY; FEMALE; HUMAN; IMMUNE RESPONSE; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MYCOSIS FUNGOIDES; OPPORTUNISTIC INFECTION; PUVA; SEZARY SYNDROME; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION;

EID: 37849187626     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.059     Document Type: Article

References (24)

1. Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003; 102:4059-4066.
2. Jensen JR, Thestrup-Pedersen K, Ahrons S, et al. The immunological profile of mycosis fungoides. Clin Exp Immunol 1982; 50:397-405.
3. Tsambiras PE, Patel S, Greene JN, et al. Infectious complications of cutaneous t-cell lymphoma. Cancer Control 2001; 8:185-188.
4. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321:1784-1790.
5. Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999; 86:1368-1376.
6. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 1995; 9:1109-1116.
7. Williams DP, Snider CE, Strom TB, et al. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990; 265:11885-11889.
8. Bacha P, Williams DP, Waters C, et al. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167:612-622.
9. Foss FM. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann N Y Acad Sci 2001; 941:166-176.
10. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T- cell lymphoma. Arch Dermatol 2001; 137:581-593.
11. LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-procein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91:399-405.
12. Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:4095-4102.
13. Dang NH, Pro B, Hagemeister FB, et al. Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed/refractory T-cell non-Hodgkin's lymphoma. Blood 2004; 104:722a (Abstract #2641).
14. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-388.
15. Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin difititox, Ontak) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001; 1:298-302.
16. Rook AH, Junkins-Hopkins JM, McGinnis KS, et al. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. Adv Dermatol 2002; 18:29-43.
17. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003; 17:1435-1448, ix. Review.
18. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Huntingt) 2000; 14:37-40.
19. Kurzrock R. Therapy of T cell lymphomas with pentostatin. Ann N Y Acad Sci 2001; 941:200-205.
20. Kong LR, Samuelson E, Rosen ST, et al. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferadve disorders. Leuk Lymphoma 1997; 26:89-97.
21. Herrmann JJ, Roenigk HH Jr, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995; 33:234-242.
22. de Coninck EC, Kim YH, Varghese A, et al. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001; 19:779-784.
23. Kim YH, Chow S, Varghese A, et al. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135:26-32.
24. Duvic M, Apisarnthanarax N, Cohen DS, et al. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003; 49:35-49.